1. Biosten LLC:
Developing bioresorbable endovascular stents

2. Cardiovascular diseases take more lives in
Russia than other mortality causes combined
0
200
400
600
800
1000
1200
Infections Respiratory
diseases
Digestive diseases External causes Cancer Cardio- vascular
diseases
Mortalityin2011г.,thousands
Mortality causes in Russia

3. Coronary stents decrease mortality from
coronary artery disease and
acute coronary syndrome
• Coronary stent opens the narrowed vessel and restores
normal blood flow
• Coronary stenting reduce hospital mortality in patients with
acute coronary syndrome by 75%

4. In coronary stenting, Russia lags behind
0
10
20
30
40
50
60
USA EU27 Russia
Coronary stents
annual use per 10000
• More than 1.5 million
coronary stents used in
USA annually.
• About 1 million coronary
stents used in EU.
• Only 77 thousand coronary
stents used in Russia.

5. But…
coronary stents could be better
Bare-metal stents and drug-eluting
stents with metal frames save
lives, but have their own
disadvantages
• Restenosis
• Several years of anti-clotting
medication
• Metal burden in the body

6. The 4th revolution in angioplasty:
bioresorbable stents
• Leave a naturally healed vessel
without permanent metallic
implant, allowing normal vasomotion
and late expansive remodeling.
• Minimize chronic inflammatory
effects of coating and metallic
platform, potentially shortening the
duration of dual anti-platelet therapy
• Facilitate re-intervention (PCI and
CABG)– late reexpansion possible , no
jailed sidebranches and no ‘’full
metal jacket’’.

7. Biosten LLC: developing bioresorbable stents
of the next generation
• Identifying polymer
composition with desired
resorption rate (in-vivo)
• Making polymer tubes
with certain mechanical
properties
• Laser cutting stents from
polymer tubes

8. Biosten results:
• We developed and demonstrated biodegradable stent prototypes
as a proof of project concept.
• Technology is patented and patent pending.

9. Stent prototype deployment in vessel model

10. Biosten results:
• Evaluated
biocompatibility, cytotoxicity, and
biodegradation
• Formed a project team that focuses on
commercialization and sustainability
of the R&D project
Contacts:
Dr. Oksana Manzenyuk, Project manager,
Biosten LLC , o.manzenyuk@stentex.ru